Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
BRISTAGEN vs NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Neomycin sulfate is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria. Polymyxin B sulfate is a polypeptide antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating immune cell activity.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
Otic: Instill 3-5 drops into the affected ear(s) 3-4 times daily; for acute otitis externa, a wick may be used initially.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
Neomycin: 2-3 hours (renal impairment: up to 12-24 hours). Polymyxin B: 4.5-6 hours (prolonged in renal failure). Hydrocortisone: 1.5-2 hours.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Neomycin is excreted primarily unchanged in feces (97%) after oral administration; absorbed fraction is renally excreted (30-50%). Polymyxin B is renally excreted (60%) with some biliary excretion. Hydrocortisone is metabolized hepatically and excreted renally as conjugates.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic